SCHEMBL7189153

SCHEMBL7189153

CCOC(=O)CC(NC(=O)C(C)c1ccc(C)cc1C)c1cccc(NS(=O)(=O)c2cccc(N)c2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 4/20 0.40
ALDH1A1 P00352 3/20 0.39
MAPT P10636 2/20 0.39
POLB P06746 1/20 0.38
ADRB2 P07550 3/20 0.37
ADRB1 P08588 3/20 0.37
ADRB3 P13945 3/20 0.37
HIF1A Q16665 1/20 0.37
MAPK1 P28482 1/20 0.36
HTR6 P50406 1/20 0.36
LMNA P02545 2/20 0.36
TP53 P04637 1/20 0.36
THRB P10828 1/20 0.36
KMT2A Q03164 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
HPGD P15428 1/20 0.35
MEN1 O00255 1/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7188012 0.88 POLB (0.47) PKMALDH1A1MAPTPOLBADRB2
SCHEMBL7781112 0.88 ALDH1A1 (0.53) PKMALDH1A1MAPTHIF1AMAPK1
SCHEMBL7189215 0.87 GPR88 (0.39) ALDH1A1MAPTLMNATP53THRB
SCHEMBL7189141 0.83 ALDH1A1 (0.40) PKMALDH1A1MAPTPOLBADRB2
SCHEMBL7194810 0.83 POLB (0.46) PKMALDH1A1MAPTPOLBADRB2
SCHEMBL7196506 0.81 POLB (0.47) ALDH1A1MAPTPOLBHTR6LMNA
SCHEMBL7197328 0.81 GPR119 (0.41) PKMALDH1A1MAPTPOLBADRB2
SCHEMBL3834077 0.80 ALDH1A1 (0.50) PKMALDH1A1MAPTPOLBHTR6
SCHEMBL3809843 0.79 POLB (0.40) PKMALDH1A1MAPTPOLBADRB2
SCHEMBL7193876 0.76 ALDH1A1 (0.55) PKMALDH1A1MAPTHIF1AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6589972-B2 Anticancer agents, osteoporosis, arteriosclerosis, restnosis,vision defects BAYER AKTIENGESELLSCHAFT (DE) 2003-07-08 US disclosed
EP-1147079-A2 BETA-PHENYLALANINE DERIVATIVES AS INTEGRIN ANTAGONISTS Bayer Aktiengesellschaft (DE) 2001-10-24 EP disclosed
US-20010031788-A1 Beta-phenylalanine derivatives as integrin antagonists SCHOOP ANDREAS (DE) 2001-10-18 US disclosed
US-6291503-B1 β-phenylalanine derivatives as integrin antagonists BAYER AKTIENGESELLSCHAFT (DE) 2001-09-18 US disclosed
WO-2000041469-A2 β-PHENYLALANINE DERIVATIVES AS INTEGRIN ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2000-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031788-A1 Beta-phenylalanine derivatives as integrin antagonists ITGB4, ITGA4, ITGB2 PKM 1186/4885ALDH1A1 2010/4885MAPT 3865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.